Souhaitez-vous accéder aux communiqués récents ?

New York, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "KRAS Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model" -...

Generated unprecedented 98% GEN-009 immune response frequency with ATLAS™Continued advancement of GEN-011, expect to file an IND in first half of 2020Entered into a common stock purchase agreement for...

KNOXVILLE, TN, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting, cancer immunotherapy PV-10 (rose bengal...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 22, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...

TYME Launched the Pivotal Stage of TYME-88-PANC Trial to Evaluate Oral SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic CancerTYME Presented Final Data at ESMO 2019 from SM-88...

Toronto, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) announced that Verzenio™ (abemaciclib) in combination with fulvestrant significantly extended life by a median of 9.4...

SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced  the presentation of...

NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immune-oncology cancer therapies, today...

Study results demonstrate that oral SM-88 may play a clinically meaningful role in postponing use of hormonal castration in prostate cancer patients with rising prostate-specific antigen (PSA):  More...

NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...